Gilead Sciences Posts Strong Q1 2026 Performance Driven by HIV Drug Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy GILD?
Source: Yahoo Finance
- Revenue Growth: Gilead Sciences reported a 4% year-on-year increase in total revenue for Q1 2026, reaching $7 billion, exceeding analyst expectations and demonstrating strong performance in the HIV drug sector.
- HIV Drug Sales: Of the $6.9 billion in total product sales, the HIV portfolio contributed $5 billion, growing 10% year-on-year, with Biktarvy generating $3.36 billion, up from $3.15 billion in 2025, solidifying its market leadership.
- PrEP Drug Performance: Sales of Descovy reached $807 million, a 38% increase from 2025, surpassing market expectations, while the newly launched Yeztugo achieved early success with $166 million in sales this quarter, projected to become a blockbuster product.
- New Drug Development Outlook: Gilead's anitocabtagene autoleucel (anito-cel) is under FDA review, expected to generate revenue in early 2027, with analysts believing it could be a strong contender in treating multiple myeloma, potentially reshaping the market landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to rise
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 134.060
Low
105.00
Averages
137.88
High
154.00
Current: 134.060
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada for PrEP, and others. It also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. It has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. It operates in over 35 countries worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Fluence Energy Shares Soar Nearly 30% After Upgrades
- Fluence Energy Surge: Fluence Energy's stock soared nearly 30% after its fiscal second-quarter EBITDA exceeded Wall Street estimates, following a prior session surge of about 40%, indicating strong market confidence in its growth potential and attracting more investor interest.
- Corpay Raises Guidance: Corpay shares jumped 10% after the company raised its full-year earnings guidance to a range of $26.30 to $27.10 per share, surpassing analyst expectations of $26.05, reflecting robust performance in the corporate payments sector and potentially increasing market share.
- Akamai Technologies Rises: Akamai's stock surged 20% after securing an $1.8 billion commitment from a leading U.S. frontier model provider for its Cloud Infrastructure Services, indicating strong demand in the market, while also reporting a first-quarter adjusted earnings beat that bolstered investor confidence.
- Upwork Restructuring Impact: Upwork's shares tumbled 21% following its announcement of a 24% workforce reduction to ensure profitability, despite slightly lower-than-expected first-quarter earnings and revenue, which may affect its future competitive position and investor sentiment.
See More
Gilead Sciences Posts Strong Q1 2026 Performance Driven by HIV Drug Growth
- Revenue Growth: Gilead Sciences reported a 4% year-on-year increase in total revenue for Q1 2026, reaching $7 billion, exceeding analyst expectations and demonstrating strong performance in the HIV drug sector.
- HIV Drug Sales: Of the $6.9 billion in total product sales, the HIV portfolio contributed $5 billion, growing 10% year-on-year, with Biktarvy generating $3.36 billion, up from $3.15 billion in 2025, solidifying its market leadership.
- PrEP Drug Performance: Sales of Descovy reached $807 million, a 38% increase from 2025, surpassing market expectations, while the newly launched Yeztugo achieved early success with $166 million in sales this quarter, projected to become a blockbuster product.
- New Drug Development Outlook: Gilead's anitocabtagene autoleucel (anito-cel) is under FDA review, expected to generate revenue in early 2027, with analysts believing it could be a strong contender in treating multiple myeloma, potentially reshaping the market landscape.
See More
Akamai Technologies Shares Surge 27% on $1.8 Billion Commitment
- Akamai Stock Surge: Shares of Akamai Technologies soared 27% after a leading U.S. frontier model provider committed to a $1.8 billion investment over seven years for its Cloud Infrastructure Services, enhancing market confidence and potentially driving future revenue growth.
- CoreWeave Revenue Guidance Miss: CoreWeave's second-quarter revenue guidance of $2.45 billion to $2.6 billion, with a midpoint of $2.53 billion, fell short of Wall Street's $2.69 billion expectation, resulting in a 7% stock decline, reflecting market concerns about its growth outlook.
- Microchip Earnings Beat: Microchip Technology's stock rose 3% following a fiscal fourth-quarter report that exceeded earnings and revenue expectations, with projected first-quarter revenue between $1.44 billion and nearly $1.47 billion, indicating strong performance in the semiconductor sector.
- Upwork Restructuring Plan: Upwork's announcement of a 24% workforce reduction to maintain profitability led to a 23% drop in its stock price, despite slightly lower-than-expected first-quarter earnings and revenue, showcasing the company's strategic response to evolving market conditions.
See More
Gilead Sciences Q1 2026 Earnings Call Highlights
- Significant Sales Growth: Gilead Sciences reported total product sales of $6.8 billion in Q1, an 8% year-over-year increase, with HIV sales reaching $5 billion, reflecting a robust 10% growth that underscores its strong market position and share gains in the HIV sector.
- Yeztugo Guidance Raised: Management has increased the 2026 Yeztugo sales guidance to approximately $1 billion, indicating confidence in product acceptance, while also projecting an 8% year-over-year growth in HIV sales, surpassing the previous guidance of 6%.
- Strong Financial Performance: The company reported a non-GAAP diluted EPS of $2.03, beating expectations by $0.12, with a product gross margin of 87% and an operating margin of 47%, showcasing its strengths in cost control and profitability.
- Positive Future Outlook: Management highlighted upcoming regulatory catalysts, including the priority review of BIC/LEN, which is expected to drive future revenue growth, while also noting a potential 2% growth headwind from policy changes that requires cautious navigation.
See More
Gilead Sciences Updates 2026 EPS Guidance to Loss Amid Q1 Beat
- EPS Guidance Cut: Gilead Sciences has drastically revised its 2026 non-GAAP EPS guidance from a profit of $8.45-$8.85 to a loss of $1.05-$1.65, primarily due to $11.5 billion in IPR&D charges and financing costs, which has negatively impacted market confidence.
- Sales Forecast Increased: Despite the EPS downgrade, Gilead projects full-year product sales of $30 billion to $30.4 billion, up from a prior estimate of $29.6 billion to $30 billion, indicating ongoing growth potential in its HIV and oncology treatment sectors.
- Significant HIV Growth: In Q1, Gilead's HIV franchise saw approximately a 10% year-over-year sales increase to around $5 billion, with Biktarvy alone generating about $3.4 billion, further solidifying its leadership in the antiviral market.
- Cash Flow Decline: As of March 31, 2026, Gilead's cash, cash equivalents, and marketable securities totaled $8.6 billion, down from $10.6 billion on December 31, 2025, reflecting financial pressure from acquisitions and R&D investments.
See More
Gilead Raises 2026 Sales Guidance Amid Acquisition Strategy
- Sales Guidance Increase: Gilead raised its 2026 product sales guidance to $30.0–$30.4 billion from $29.6–$30.0 billion, reflecting confidence in future growth despite pressures from acquisition-related costs.
- Aggressive Acquisition Strategy: The company is actively pursuing acquisitions, having announced deals for Arcellx, Ouro Medicines, and Tubulis since the start of 2026, aiming to bolster its oncology and inflammation pipeline while maintaining resilience in its HIV franchise.
- Strong Earnings Report: Gilead reported first-quarter revenues of $7.0 billion, a 4% year-over-year increase, with product sales rising 5% to $6.9 billion and HIV product sales growing 10% to $5.0 billion, demonstrating the strength of its core business.
- Earnings Outlook Cut: Despite the sales guidance increase, Gilead slashed its 2026 adjusted loss guidance to a range of $1.05 to $0.65 per share, down from previous earnings estimates of $8.45 to $8.85 per share, primarily due to anticipated acquisition-related charges and financing costs.
See More
Fluence Energy Shares Soar Nearly 30% After Upgrades
- Fluence Energy Surge: Fluence Energy's stock soared nearly 30% after its fiscal second-quarter EBITDA exceeded Wall Street estimates, following a prior session surge of about 40%, indicating strong market confidence in its growth potential and attracting more investor interest.
- Corpay Raises Guidance: Corpay shares jumped 10% after the company raised its full-year earnings guidance to a range of $26.30 to $27.10 per share, surpassing analyst expectations of $26.05, reflecting robust performance in the corporate payments sector and potentially increasing market share.
- Akamai Technologies Rises: Akamai's stock surged 20% after securing an $1.8 billion commitment from a leading U.S. frontier model provider for its Cloud Infrastructure Services, indicating strong demand in the market, while also reporting a first-quarter adjusted earnings beat that bolstered investor confidence.
- Upwork Restructuring Impact: Upwork's shares tumbled 21% following its announcement of a 24% workforce reduction to ensure profitability, despite slightly lower-than-expected first-quarter earnings and revenue, which may affect its future competitive position and investor sentiment.
See More
Gilead Sciences Posts Strong Q1 2026 Performance Driven by HIV Drug Growth
- Revenue Growth: Gilead Sciences reported a 4% year-on-year increase in total revenue for Q1 2026, reaching $7 billion, exceeding analyst expectations and demonstrating strong performance in the HIV drug sector.
- HIV Drug Sales: Of the $6.9 billion in total product sales, the HIV portfolio contributed $5 billion, growing 10% year-on-year, with Biktarvy generating $3.36 billion, up from $3.15 billion in 2025, solidifying its market leadership.
- PrEP Drug Performance: Sales of Descovy reached $807 million, a 38% increase from 2025, surpassing market expectations, while the newly launched Yeztugo achieved early success with $166 million in sales this quarter, projected to become a blockbuster product.
- New Drug Development Outlook: Gilead's anitocabtagene autoleucel (anito-cel) is under FDA review, expected to generate revenue in early 2027, with analysts believing it could be a strong contender in treating multiple myeloma, potentially reshaping the market landscape.
See More
Akamai Technologies Shares Surge 27% on $1.8 Billion Commitment
- Akamai Stock Surge: Shares of Akamai Technologies soared 27% after a leading U.S. frontier model provider committed to a $1.8 billion investment over seven years for its Cloud Infrastructure Services, enhancing market confidence and potentially driving future revenue growth.
- CoreWeave Revenue Guidance Miss: CoreWeave's second-quarter revenue guidance of $2.45 billion to $2.6 billion, with a midpoint of $2.53 billion, fell short of Wall Street's $2.69 billion expectation, resulting in a 7% stock decline, reflecting market concerns about its growth outlook.
- Microchip Earnings Beat: Microchip Technology's stock rose 3% following a fiscal fourth-quarter report that exceeded earnings and revenue expectations, with projected first-quarter revenue between $1.44 billion and nearly $1.47 billion, indicating strong performance in the semiconductor sector.
- Upwork Restructuring Plan: Upwork's announcement of a 24% workforce reduction to maintain profitability led to a 23% drop in its stock price, despite slightly lower-than-expected first-quarter earnings and revenue, showcasing the company's strategic response to evolving market conditions.
See More
Gilead Sciences Q1 2026 Earnings Call Highlights
- Significant Sales Growth: Gilead Sciences reported total product sales of $6.8 billion in Q1, an 8% year-over-year increase, with HIV sales reaching $5 billion, reflecting a robust 10% growth that underscores its strong market position and share gains in the HIV sector.
- Yeztugo Guidance Raised: Management has increased the 2026 Yeztugo sales guidance to approximately $1 billion, indicating confidence in product acceptance, while also projecting an 8% year-over-year growth in HIV sales, surpassing the previous guidance of 6%.
- Strong Financial Performance: The company reported a non-GAAP diluted EPS of $2.03, beating expectations by $0.12, with a product gross margin of 87% and an operating margin of 47%, showcasing its strengths in cost control and profitability.
- Positive Future Outlook: Management highlighted upcoming regulatory catalysts, including the priority review of BIC/LEN, which is expected to drive future revenue growth, while also noting a potential 2% growth headwind from policy changes that requires cautious navigation.
See More
Gilead Sciences Updates 2026 EPS Guidance to Loss Amid Q1 Beat
- EPS Guidance Cut: Gilead Sciences has drastically revised its 2026 non-GAAP EPS guidance from a profit of $8.45-$8.85 to a loss of $1.05-$1.65, primarily due to $11.5 billion in IPR&D charges and financing costs, which has negatively impacted market confidence.
- Sales Forecast Increased: Despite the EPS downgrade, Gilead projects full-year product sales of $30 billion to $30.4 billion, up from a prior estimate of $29.6 billion to $30 billion, indicating ongoing growth potential in its HIV and oncology treatment sectors.
- Significant HIV Growth: In Q1, Gilead's HIV franchise saw approximately a 10% year-over-year sales increase to around $5 billion, with Biktarvy alone generating about $3.4 billion, further solidifying its leadership in the antiviral market.
- Cash Flow Decline: As of March 31, 2026, Gilead's cash, cash equivalents, and marketable securities totaled $8.6 billion, down from $10.6 billion on December 31, 2025, reflecting financial pressure from acquisitions and R&D investments.
See More
Gilead Raises 2026 Sales Guidance Amid Acquisition Strategy
- Sales Guidance Increase: Gilead raised its 2026 product sales guidance to $30.0–$30.4 billion from $29.6–$30.0 billion, reflecting confidence in future growth despite pressures from acquisition-related costs.
- Aggressive Acquisition Strategy: The company is actively pursuing acquisitions, having announced deals for Arcellx, Ouro Medicines, and Tubulis since the start of 2026, aiming to bolster its oncology and inflammation pipeline while maintaining resilience in its HIV franchise.
- Strong Earnings Report: Gilead reported first-quarter revenues of $7.0 billion, a 4% year-over-year increase, with product sales rising 5% to $6.9 billion and HIV product sales growing 10% to $5.0 billion, demonstrating the strength of its core business.
- Earnings Outlook Cut: Despite the sales guidance increase, Gilead slashed its 2026 adjusted loss guidance to a range of $1.05 to $0.65 per share, down from previous earnings estimates of $8.45 to $8.85 per share, primarily due to anticipated acquisition-related charges and financing costs.
See More
